180 related articles for article (PubMed ID: 35721889)
41. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
Jiang JW; Chen XH; Ren Z; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
[TBL] [Abstract][Full Text] [Related]
42. Inflammatory Milieu Related to Dysbiotic Gut Microbiota Promotes Tumorigenesis of Hepatocellular Carcinoma.
Huang C; Mei S; Zhang X; Tian X
J Clin Gastroenterol; 2023 Sep; 57(8):782-788. PubMed ID: 37406184
[TBL] [Abstract][Full Text] [Related]
43. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
Lee PC; Wu CJ; Hung YW; Lee CJ; Chi CT; Lee IC; Yu-Lun K; Chou SH; Luo JC; Hou MC; Huang YH
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738801
[TBL] [Abstract][Full Text] [Related]
44. Immunotherapy as a Downstaging Therapy for Liver Transplantation.
Schwacha-Eipper B; Minciuna I; Banz V; Dufour JF
Hepatology; 2020 Oct; 72(4):1488-1490. PubMed ID: 32171041
[No Abstract] [Full Text] [Related]
45. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.
Yi M; Jiao D; Qin S; Chu Q; Li A; Wu K
Integr Cancer Ther; 2019; 18():1534735419876351. PubMed ID: 31517538
[TBL] [Abstract][Full Text] [Related]
46. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
47. Nivolumab for the treatment of hepatocellular carcinoma.
Chiew Woon L; Joycelyn Jie Xin L; Su Pin C
Expert Opin Biol Ther; 2020 Jul; 20(7):687-693. PubMed ID: 32249635
[TBL] [Abstract][Full Text] [Related]
48. PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA.
Uhlig J; Stein S; Kim HS
Future Oncol; 2022 May; 18(14):1691-1703. PubMed ID: 35172633
[TBL] [Abstract][Full Text] [Related]
49. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
50. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.
Fessas P; Kaseb A; Wang Y; Saeed A; Szafron D; Jun T; Dharmapuri S; Rafeh Naqash A; Muzaffar M; Navaid M; Khan U; Lee C; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Benevento F; Hildebrand H; Pressiani T; Abugabal YI; Personeni N; Huang YH; Rimassa L; Ang C; Marron T; Pinato DJ
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868393
[TBL] [Abstract][Full Text] [Related]
51. Advances in research on the relationship between the gut microbiome and cancer.
Song P; Wang QB; Liang B; Jiang SJ
Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5104-5112. PubMed ID: 34486684
[TBL] [Abstract][Full Text] [Related]
52. Hepatocellular Cancer and Gut Microbiome: Time to Untie Gordian's Knot.
Aygün C; Tözün N
J Gastrointest Cancer; 2021 Dec; 52(4):1309-1313. PubMed ID: 34750696
[TBL] [Abstract][Full Text] [Related]
53. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
[TBL] [Abstract][Full Text] [Related]
54. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
55. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Bangaru S; Marrero JA; Singal AG
Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
[TBL] [Abstract][Full Text] [Related]
56. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.
Sun D; Liu D; Liu Q; Hou H
Cancer Biol Ther; 2020 Dec; 21(12):1097-1104. PubMed ID: 33151119
[TBL] [Abstract][Full Text] [Related]
57. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T; Park JW; Finn RS; Cheng AL; Mathurin P; Edeline J; Kudo M; Harding JJ; Merle P; Rosmorduc O; Wyrwicz L; Schott E; Choo SP; Kelley RK; Sieghart W; Assenat E; Zaucha R; Furuse J; Abou-Alfa GK; El-Khoueiry AB; Melero I; Begic D; Chen G; Neely J; Wisniewski T; Tschaika M; Sangro B
Lancet Oncol; 2022 Jan; 23(1):77-90. PubMed ID: 34914889
[TBL] [Abstract][Full Text] [Related]
58. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.
Zheng Y; Wang T; Tu X; Huang Y; Zhang H; Tan D; Jiang W; Cai S; Zhao P; Song R; Li P; Qin N; Fang W
J Immunother Cancer; 2019 Jul; 7(1):193. PubMed ID: 31337439
[TBL] [Abstract][Full Text] [Related]
59. Treatment of inoperable hepatocellular carcinoma with immunotherapy.
Tighe SP; Iqbal U; Fernandes CT; Ahmed A
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31352386
[TBL] [Abstract][Full Text] [Related]
60. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
Oh B; Boyle F; Pavlakis N; Clarke S; Eade T; Hruby G; Lamoury G; Carroll S; Morgia M; Kneebone A; Stevens M; Liu W; Corless B; Molloy M; Kong B; Libermann T; Rosenthal D; Back M
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638308
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
